1. Home
  2. ALX vs AUTL Comparison

ALX vs AUTL Comparison

Compare ALX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALX
  • AUTL
  • Stock Information
  • Founded
  • ALX 1928
  • AUTL 2014
  • Country
  • ALX United States
  • AUTL United Kingdom
  • Employees
  • ALX N/A
  • AUTL N/A
  • Industry
  • ALX Real Estate Investment Trusts
  • AUTL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ALX Real Estate
  • AUTL Health Care
  • Exchange
  • ALX Nasdaq
  • AUTL Nasdaq
  • Market Cap
  • ALX 1.2B
  • AUTL 625.4M
  • IPO Year
  • ALX N/A
  • AUTL 2018
  • Fundamental
  • Price
  • ALX $228.01
  • AUTL $2.37
  • Analyst Decision
  • ALX Sell
  • AUTL Strong Buy
  • Analyst Count
  • ALX 1
  • AUTL 5
  • Target Price
  • ALX $125.00
  • AUTL $9.32
  • AVG Volume (30 Days)
  • ALX 77.9K
  • AUTL 2.1M
  • Earning Date
  • ALX 08-04-2025
  • AUTL 08-07-2025
  • Dividend Yield
  • ALX 7.74%
  • AUTL N/A
  • EPS Growth
  • ALX N/A
  • AUTL N/A
  • EPS
  • ALX 7.72
  • AUTL N/A
  • Revenue
  • ALX $219,892,000.00
  • AUTL $9,011,000.00
  • Revenue This Year
  • ALX N/A
  • AUTL $461.76
  • Revenue Next Year
  • ALX N/A
  • AUTL $112.66
  • P/E Ratio
  • ALX $29.91
  • AUTL N/A
  • Revenue Growth
  • ALX N/A
  • AUTL N/A
  • 52 Week Low
  • ALX $184.76
  • AUTL $1.11
  • 52 Week High
  • ALX $251.63
  • AUTL $5.00
  • Technical
  • Relative Strength Index (RSI)
  • ALX 59.30
  • AUTL 70.63
  • Support Level
  • ALX $222.50
  • AUTL $2.20
  • Resistance Level
  • ALX $231.23
  • AUTL $2.44
  • Average True Range (ATR)
  • ALX 5.25
  • AUTL 0.12
  • MACD
  • ALX -0.04
  • AUTL -0.01
  • Stochastic Oscillator
  • ALX 89.65
  • AUTL 84.95

About ALX Alexander's Inc.

Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Share on Social Networks: